GlassScriptPhysician profile
David F Hutcheon
NPI 1679551865
$4,662.70
in general payments reported to CMS, 2019-2025
32 companies · $431 in 2025
The $431 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,395 · 2020: $677 · 2021: $583 · 2022: $574 · 2023: $476 · 2024: $526 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,456.74 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $584.78 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $527.33 | 2019-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $241.85 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $216.11 | 2019-2023 | Sucraid |
| Allergan, INC. | $207.04 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $153.36 | 2020-2024 | Ocaliva |
| Daiichi Sankyo INC. | $136.42 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $136.39 | 2023 | Zeposia |
| Janssen Biotech, INC. | $119.79 | 2019-2024 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $84.51 | 2024-2025 | Omvoh |
| Pfizer INC. | $75.92 | 2019-2020 | |
| Celgene Corporation | $71.69 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $68.32 | 2024 | |
| Ucb, INC. | $68.32 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $59.24 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $45.76 | 2022-2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $44.31 | 2019-2020 | |
| Celltrion USA INC. | $43.11 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $42.32 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $41.92 | 2019-2021 | |
| Gilead Sciences, INC. | $39.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.28 | 2024 | Cyltezo |
| Madrigal Pharmaceuticals | $28.43 | 2025 | Rezdiffra |
| Shire North American Group INC | $20.72 | 2019 | |
| Medtronic, INC. | $18.04 | 2024 | Minimed 780g |
| Ironwood Pharmaceuticals, INC | $17.65 | 2019 | |
| Orphalan INC | $17.51 | 2024 | Cuvrior |
| Intra-Sana Laboratories | $17.51 | 2022 | |
| Merck Sharp & Dohme LLC | $16.18 | 2024 | Dificid, Zinplava |
| Merit Medical Systems INC | $16.05 | 2023 | Elation Balloon Dilator |
| Alfasigma USA, INC. | $15.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hutcheon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.